GLP-1 Peptide Atlas, by Delfa

CompletedPhase 1

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants

A Phase I Randomised Single-blind Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of AZD9550 Following Single Ascending Dose Administration to Healthy Participants

Lead sponsor

AstraZeneca

Asset

AZD9550

Subcutaneous · GLP-1 / glucagon dual

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Healthy volunteers

Key I/E criteria

•BMI 18-30•Healthy volunteers

Primary endpoint

•Adverse Events (AEs) and Serious Adverse Events (SAEs)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05848440

Org study IDD8460C00001

Secondary ID2022-003308-34

Timeline

Milestones

Study start2023-05-02actual

Study first posted2023-05-08actual

Primary completion2023-11-13actual

Study completion2023-11-13actual

Last update posted2023-12-11actual

Assets

Investigational agents

AZD9550

Study populations

Who this study enrolls

Healthy volunteers

Eligibility

Who can enroll

Minimum age18 Years

Maximum age55 Years

SexAll

Healthy volunteersAccepted

Inclusion criteria

•Provision of signed and dated, written informed consent prior to any study-specific procedures.

•Healthy male and female participants aged 18 to 55 years.

•Females must have a negative pregnancy test at the Screening Visit and on admission to the Clinical Unit, must not be lactating, and must be of non childbearing potential, confirmed at the Screening Visit by fulfilling one of the following criteria:

1. Postmenopausal defined as amenorrhoea for at least 12 months or more following cessation of all exogenous hormonal treatments and Follicle stimulating hormone (FSH) levels in the postmenopausal range.

2. Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation.

•Have a Body mass index (BMI) between 18 and 30 kg/m^2 inclusive and weigh at least 50 kg and no more than 100 kg inclusive at Screening and admission.

Exclusion criteria

•History of any clinically important disease or disorder which, in the opinion of the Investigator, may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study.

•History or presence of gastrointestinal, hepatic or renal disease or any other condition known to interfere with absorption, distribution, metabolism or excretion of drugs.

•Any clinically important illness, medical/surgical procedure or trauma within 4 weeks of the first administration of Investigational medicinal product (IMP).

•Any laboratory values with the following deviations at Screening and admission:

1. Alanine aminotransferase > Upper limit of normal (ULN)

2. Aspartate aminotransferase > ULN

3. eGFR < 60 mL/min/1.73m2 (to be calculated using CKD-EPI formula)

4. White blood cell count < LLN

5. Hemoglobin < LLN

6. Neutrophil Count <1.5 × 10*9/L

•Any clinically important abnormalities in clinical chemistry, haematology or urinalysis results other than those described under exclusion criterion number 4, as judged by the Investigator.

•Any positive result at Screening for serum hepatitis B surface antigen, hepatitis C antibody and Human immunodeficiency virus (HIV).

•Abnormal vital signs, after 10 minutes supine rest at Screening.

•Any clinically important abnormalities in rhythm, conduction or morphology of the resting Electrocardiogram (ECG) and any clinically important abnormalities in the 12 lead ECG that may interfere with the interpretation of QTc interval changes, including abnormal ST T wave morphology, particularly in the protocol defined primary lead or left ventricular hypertrophy.

•History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, as judged by the Investigator or history of hypersensitivity to drugs with a similar chemical structure or class to AZD9550.

•Plasma donation within one month of the Screening Visit or any blood donation/blood loss > 500 mL during the 3 months prior to the Screening Visit.

•Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 3 months of the first administration of IMP in this study. The period of exclusion begins 3 months after the final dose or one month after the last visit whichever is the longest.

Note: participants consented and screened, but not randomised in this study or a previous Phase I study, are not excluded.

•Judgment by the Investigator that the participant should not participate in the study if they have any ongoing or recent (ie, during the Screening period) minor medical complaints that may interfere with the interpretation of study data or are considered unlikely to comply with study procedures, restrictions and requirements.

•Participants with a medical history of Medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome (MEN 2), or a baseline serum calcitonin at or above 50 ng/L.

•Any condition that would have interfered with the evaluation of the IMP or interpretation of participant safety or study results.

•Participants who are unable to consume in full the MMTT (Mixed meal tolerance test - Ensure Plus 200 mL).

•Participants with a medical history of MTC (Medullary thyroid carcinoma) or MEN 2 (multiple endocrine neoplasia syndrome), or a baseline serum calcitonin at or above 50 ng/L.

Endpoints (5)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Safety / tolerability / PK

5 endpoints

Primary/protocol endpoint

Adverse Events (AEs) and Serious Adverse Events (SAEs)

Time frame:Throughout the study (up to 6 months)

descriptive

Secondary/protocol endpoint

Area under concentration time curve from time 0 to infinity (AUCinf)

Time frame:Day 1 until Day 43 (follow-up visit)

concentration, descriptive

Secondary/protocol endpoint

Area under concentration-time curve from time 0 to the last quantifiable concentration (AUClast)

Time frame:Day 1 until Day 43 (follow-up visit)

concentration, descriptive

Secondary/protocol endpoint

Maximum observed concentration (Cmax)

Time frame:Day 1 until Day 43 (follow-up visit)

concentration, descriptive

Secondary/protocol endpoint

Incidence of Anti-Drug Antibodies (ADAs)

Time frame:Day 1 until Day 43 (follow-up visit)

event count, event

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.